https://scholars.lib.ntu.edu.tw/handle/123456789/473724
Title: | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | Authors: | CHING-YAO YANG WEI-YU LIAO CHAO-CHI HO KUAN-YU CHEN TZU-HSIU TSAI CHIA-LIN HSU KANG-YI SU YIH-LEONG CHANG CHEN-TU WU Chia-Chi Hsu BIN-CHI LIAO Wei-Hsun Hsu JIH-HSIANG LEE CHIA-CHI LIN JIN-YUAN SHIH CHIH-HSIN YANG CHONG-JEN YU |
Issue Date: | 2020 | Publisher: | Elsevier Ltd | Journal Volume: | 124 | Start page/Pages: | 110-122 | Source: | European Journal of Cancer | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075197555&doi=10.1016%2fj.ejca.2019.10.019&partnerID=40&md5=391f584152d33a462097b5a001f16015 https://scholars.lib.ntu.edu.tw/handle/123456789/473724 |
ISSN: | 0959-8049 | DOI: | 10.1016/j.ejca.2019.10.019 | SDG/Keyword: | epidermal growth factor receptor; programmed death 1 ligand 1; protein tyrosine kinase inhibitor; CD274 protein, human; EGFR protein, human; epidermal growth factor receptor; programmed death 1 ligand 1; protein kinase inhibitor; adult; aged; Article; cancer prognosis; cancer resistance; cancer survival; clinical outcome; cohort analysis; controlled study; drug efficacy; female; gene mutation; human; immunohistochemistry; lung adenocarcinoma; major clinical study; male; priority journal; progression free survival; protein expression; protein expression level; retrospective study; Taiwanese; tumor microenvironment; biosynthesis; genetics; immunology; lung adenocarcinoma; lung tumor; middle aged; mutation; pathology; tumor microenvironment; very elderly; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; B7-H1 Antigen; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Tumor Microenvironment |
Appears in Collections: | 病理學科所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.